| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Imaging | 85 | 2026 | 3612 | 5.650 |
Why?
|
| Contrast Media | 56 | 2026 | 1013 | 5.440 |
Why?
|
| Prostatic Neoplasms | 37 | 2025 | 1842 | 3.360 |
Why?
|
| Image Enhancement | 20 | 2021 | 503 | 1.900 |
Why?
|
| Algorithms | 14 | 2026 | 2003 | 1.510 |
Why?
|
| Breast | 10 | 2026 | 316 | 1.490 |
Why?
|
| Image Processing, Computer-Assisted | 17 | 2026 | 1304 | 1.420 |
Why?
|
| Gadolinium DTPA | 17 | 2024 | 239 | 1.400 |
Why?
|
| Models, Theoretical | 10 | 2026 | 509 | 1.290 |
Why?
|
| Breast Neoplasms | 22 | 2026 | 3285 | 1.240 |
Why?
|
| Image Interpretation, Computer-Assisted | 13 | 2019 | 643 | 1.030 |
Why?
|
| Ultrasonic Therapy | 6 | 2012 | 44 | 0.920 |
Why?
|
| Prostate | 11 | 2023 | 434 | 0.910 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 12 | 2023 | 304 | 0.910 |
Why?
|
| Mammary Glands, Animal | 8 | 2020 | 82 | 0.900 |
Why?
|
| Signal-To-Noise Ratio | 4 | 2021 | 128 | 0.890 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 6 | 2026 | 135 | 0.870 |
Why?
|
| Mammary Neoplasms, Experimental | 7 | 2015 | 130 | 0.830 |
Why?
|
| Arteries | 4 | 2021 | 172 | 0.810 |
Why?
|
| Reproducibility of Results | 23 | 2026 | 2792 | 0.800 |
Why?
|
| Ultrasonics | 7 | 2012 | 38 | 0.770 |
Why?
|
| Computer Simulation | 11 | 2021 | 1147 | 0.760 |
Why?
|
| Mammary Neoplasms, Animal | 4 | 2020 | 59 | 0.690 |
Why?
|
| Models, Biological | 14 | 2025 | 1805 | 0.660 |
Why?
|
| Muscle, Skeletal | 7 | 2020 | 523 | 0.620 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2014 | 166 | 0.610 |
Why?
|
| Phantoms, Imaging | 5 | 2015 | 493 | 0.510 |
Why?
|
| Carcinoma in Situ | 2 | 2015 | 55 | 0.510 |
Why?
|
| Organometallic Compounds | 4 | 2021 | 142 | 0.510 |
Why?
|
| Sensitivity and Specificity | 16 | 2023 | 1945 | 0.490 |
Why?
|
| Animals | 51 | 2025 | 28981 | 0.480 |
Why?
|
| Rats | 18 | 2017 | 4074 | 0.480 |
Why?
|
| Male | 47 | 2025 | 47263 | 0.440 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2020 | 283 | 0.430 |
Why?
|
| Humans | 77 | 2026 | 98370 | 0.430 |
Why?
|
| Hyperthermia, Induced | 5 | 2012 | 77 | 0.390 |
Why?
|
| Middle Aged | 38 | 2026 | 29532 | 0.380 |
Why?
|
| Neoplasms, Experimental | 2 | 2005 | 263 | 0.370 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2020 | 631 | 0.370 |
Why?
|
| Blood-Brain Barrier | 3 | 2025 | 87 | 0.360 |
Why?
|
| Female | 47 | 2026 | 51761 | 0.350 |
Why?
|
| Biomimetic Materials | 1 | 2012 | 25 | 0.350 |
Why?
|
| Neoplasm Transplantation | 6 | 2010 | 400 | 0.340 |
Why?
|
| Abdominal Abscess | 1 | 2011 | 24 | 0.340 |
Why?
|
| Mice | 28 | 2025 | 12735 | 0.340 |
Why?
|
| Tumor Hypoxia | 2 | 2022 | 53 | 0.330 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2012 | 54 | 0.330 |
Why?
|
| Subtraction Technique | 3 | 2009 | 126 | 0.330 |
Why?
|
| Neoadjuvant Therapy | 2 | 2026 | 478 | 0.330 |
Why?
|
| Meglumine | 3 | 2021 | 36 | 0.320 |
Why?
|
| Camellia sinensis | 1 | 2009 | 6 | 0.300 |
Why?
|
| Angiogenesis Modulating Agents | 1 | 2009 | 4 | 0.300 |
Why?
|
| Aged | 23 | 2026 | 21844 | 0.290 |
Why?
|
| Peripheral Arterial Disease | 2 | 2021 | 110 | 0.280 |
Why?
|
| Neovascularization, Pathologic | 5 | 2015 | 356 | 0.280 |
Why?
|
| Fluorine | 2 | 2005 | 11 | 0.280 |
Why?
|
| Computed Tomography Angiography | 2 | 2021 | 190 | 0.280 |
Why?
|
| Fourier Analysis | 5 | 2016 | 124 | 0.270 |
Why?
|
| Diet, High-Fat | 2 | 2020 | 144 | 0.270 |
Why?
|
| Plant Extracts | 1 | 2009 | 252 | 0.260 |
Why?
|
| Pilot Projects | 11 | 2024 | 970 | 0.260 |
Why?
|
| Adult | 24 | 2026 | 29587 | 0.250 |
Why?
|
| Laser Therapy | 2 | 2018 | 149 | 0.250 |
Why?
|
| Carcinogenesis | 2 | 2020 | 244 | 0.250 |
Why?
|
| Adipose Tissue | 2 | 2006 | 280 | 0.240 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2025 | 661 | 0.240 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2006 | 12 | 0.240 |
Why?
|
| Retrospective Studies | 14 | 2026 | 11043 | 0.230 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2020 | 218 | 0.230 |
Why?
|
| Fluorocarbons | 1 | 2005 | 64 | 0.230 |
Why?
|
| Ultrasonography | 4 | 2014 | 720 | 0.230 |
Why?
|
| Echo-Planar Imaging | 5 | 2008 | 49 | 0.220 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2002 | 271 | 0.220 |
Why?
|
| Misonidazole | 2 | 2022 | 19 | 0.210 |
Why?
|
| Prostatectomy | 6 | 2023 | 491 | 0.210 |
Why?
|
| Body Water | 3 | 2004 | 34 | 0.210 |
Why?
|
| Gadolinium | 2 | 2018 | 95 | 0.210 |
Why?
|
| Muscle Neoplasms | 1 | 2004 | 16 | 0.200 |
Why?
|
| Neoplasm Grading | 5 | 2026 | 425 | 0.200 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2023 | 153 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2023 | 463 | 0.200 |
Why?
|
| Myocardium | 1 | 2006 | 578 | 0.200 |
Why?
|
| Thorax | 2 | 2000 | 77 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 5 | 2020 | 583 | 0.190 |
Why?
|
| Mice, Transgenic | 7 | 2018 | 1607 | 0.190 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 216 | 0.190 |
Why?
|
| Carbon Dioxide | 2 | 2002 | 201 | 0.180 |
Why?
|
| Oxygen | 4 | 2021 | 773 | 0.180 |
Why?
|
| Water | 4 | 2009 | 309 | 0.180 |
Why?
|
| Feasibility Studies | 7 | 2020 | 817 | 0.180 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 118 | 0.170 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2023 | 186 | 0.170 |
Why?
|
| Neoplasms | 7 | 2020 | 3349 | 0.160 |
Why?
|
| Rats, Inbred F344 | 4 | 2005 | 161 | 0.160 |
Why?
|
| Cognition | 1 | 2025 | 669 | 0.160 |
Why?
|
| Leg | 1 | 2021 | 145 | 0.160 |
Why?
|
| Diagnosis, Differential | 6 | 2026 | 1570 | 0.160 |
Why?
|
| Acoustics | 2 | 1997 | 49 | 0.160 |
Why?
|
| Time Factors | 8 | 2025 | 5577 | 0.150 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2020 | 107 | 0.150 |
Why?
|
| Electromagnetic Fields | 1 | 1999 | 26 | 0.140 |
Why?
|
| Microvessels | 2 | 2009 | 70 | 0.140 |
Why?
|
| Ischemia | 1 | 2021 | 263 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2020 | 112 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 2678 | 0.140 |
Why?
|
| Disease Models, Animal | 8 | 2020 | 2577 | 0.140 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2018 | 34 | 0.140 |
Why?
|
| Dietary Sugars | 1 | 2018 | 8 | 0.140 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2018 | 11 | 0.130 |
Why?
|
| Diet, Fat-Restricted | 1 | 2018 | 30 | 0.130 |
Why?
|
| Information Storage and Retrieval | 2 | 2010 | 129 | 0.130 |
Why?
|
| Prostatic Hyperplasia | 1 | 2019 | 104 | 0.130 |
Why?
|
| Pulse Wave Analysis | 1 | 2017 | 9 | 0.130 |
Why?
|
| Hindlimb | 3 | 2010 | 100 | 0.130 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 843 | 0.130 |
Why?
|
| Androgen Antagonists | 3 | 2023 | 157 | 0.130 |
Why?
|
| Feeding Behavior | 1 | 2020 | 352 | 0.130 |
Why?
|
| Therapy, Computer-Assisted | 2 | 1995 | 20 | 0.130 |
Why?
|
| Wrist | 1 | 2017 | 30 | 0.130 |
Why?
|
| Prospective Studies | 6 | 2018 | 4818 | 0.130 |
Why?
|
| Oxides | 3 | 2002 | 42 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2018 | 145 | 0.130 |
Why?
|
| Dietary Fats | 1 | 2017 | 135 | 0.120 |
Why?
|
| Brain | 3 | 2025 | 2439 | 0.120 |
Why?
|
| Iron | 3 | 2002 | 178 | 0.120 |
Why?
|
| Immunohistochemistry | 4 | 2016 | 1817 | 0.120 |
Why?
|
| Durapatite | 1 | 2015 | 36 | 0.110 |
Why?
|
| Observer Variation | 2 | 2021 | 579 | 0.110 |
Why?
|
| Biopsy | 6 | 2019 | 1225 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 1107 | 0.110 |
Why?
|
| ROC Curve | 5 | 2018 | 793 | 0.110 |
Why?
|
| Cluster Analysis | 2 | 2026 | 400 | 0.110 |
Why?
|
| Evaluation Studies as Topic | 3 | 2006 | 244 | 0.110 |
Why?
|
| Kinetics | 5 | 2023 | 1477 | 0.110 |
Why?
|
| Calcium Oxalate | 1 | 2015 | 192 | 0.100 |
Why?
|
| Metal Nanoparticles | 1 | 2014 | 37 | 0.100 |
Why?
|
| Gold | 1 | 2014 | 45 | 0.100 |
Why?
|
| Reference Values | 2 | 2015 | 608 | 0.100 |
Why?
|
| Temperature | 4 | 1999 | 442 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 111 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2014 | 285 | 0.100 |
Why?
|
| Oncolytic Virotherapy | 1 | 2013 | 36 | 0.100 |
Why?
|
| Thermometers | 3 | 1999 | 6 | 0.100 |
Why?
|
| Models, Anatomic | 2 | 1998 | 88 | 0.100 |
Why?
|
| Crohn Disease | 2 | 2011 | 859 | 0.090 |
Why?
|
| Manganese Compounds | 1 | 2012 | 6 | 0.090 |
Why?
|
| Neural Stem Cells | 1 | 2013 | 73 | 0.090 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2013 | 86 | 0.090 |
Why?
|
| Cell Line, Tumor | 4 | 2023 | 2896 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 1028 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2023 | 286 | 0.090 |
Why?
|
| Transducers | 3 | 1997 | 37 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 4 | 2015 | 118 | 0.090 |
Why?
|
| Niacinamide | 1 | 2012 | 105 | 0.090 |
Why?
|
| Disease Progression | 2 | 2014 | 1615 | 0.090 |
Why?
|
| Chlorides | 1 | 2012 | 102 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2013 | 195 | 0.090 |
Why?
|
| Scattering, Radiation | 1 | 1992 | 122 | 0.090 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 112 | 0.090 |
Why?
|
| Glioma | 1 | 2014 | 309 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2015 | 563 | 0.090 |
Why?
|
| Tissue Culture Techniques | 1 | 2011 | 81 | 0.080 |
Why?
|
| Ascites | 1 | 2011 | 55 | 0.080 |
Why?
|
| Proteomics | 2 | 2023 | 280 | 0.080 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 226 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 302 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2011 | 92 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 325 | 0.080 |
Why?
|
| Diffusion | 3 | 2013 | 95 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2013 | 300 | 0.080 |
Why?
|
| Swine | 1 | 2012 | 593 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 281 | 0.080 |
Why?
|
| X-Ray Microtomography | 1 | 2011 | 109 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 468 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2212 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 822 | 0.080 |
Why?
|
| Injections | 3 | 2017 | 131 | 0.080 |
Why?
|
| Pregnancy | 3 | 2025 | 3269 | 0.080 |
Why?
|
| Positron-Emission Tomography | 2 | 2022 | 354 | 0.080 |
Why?
|
| Macrophages | 2 | 2023 | 643 | 0.070 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 2022 | 340 | 0.070 |
Why?
|
| Glucose | 1 | 2012 | 704 | 0.070 |
Why?
|
| Extracellular Space | 1 | 2009 | 84 | 0.070 |
Why?
|
| Radiation Dosage | 2 | 2021 | 232 | 0.070 |
Why?
|
| Perfusion Imaging | 1 | 2009 | 52 | 0.070 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2009 | 9 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2011 | 321 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2009 | 88 | 0.070 |
Why?
|
| Breast Diseases | 2 | 2011 | 101 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2012 | 453 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 7418 | 0.070 |
Why?
|
| Artifacts | 2 | 2015 | 248 | 0.070 |
Why?
|
| Mice, Nude | 4 | 2013 | 830 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 639 | 0.070 |
Why?
|
| Leiomyoma | 1 | 2012 | 225 | 0.070 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2006 | 197 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2020 | 331 | 0.070 |
Why?
|
| Uterine Neoplasms | 1 | 2012 | 289 | 0.060 |
Why?
|
| Ferrosoferric Oxide | 3 | 2002 | 19 | 0.060 |
Why?
|
| Dextrans | 3 | 2002 | 77 | 0.060 |
Why?
|
| Magnetite Nanoparticles | 3 | 2002 | 27 | 0.060 |
Why?
|
| Equipment Design | 2 | 2006 | 425 | 0.060 |
Why?
|
| Colitis | 1 | 2010 | 264 | 0.060 |
Why?
|
| Protons | 2 | 2008 | 102 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2009 | 375 | 0.060 |
Why?
|
| Materials Testing | 1 | 2006 | 95 | 0.060 |
Why?
|
| Hypoxia | 2 | 2022 | 682 | 0.060 |
Why?
|
| Emulsions | 1 | 2005 | 20 | 0.060 |
Why?
|
| Hot Temperature | 2 | 2014 | 228 | 0.060 |
Why?
|
| Germ-Free Life | 1 | 2025 | 88 | 0.060 |
Why?
|
| Carcinoma | 1 | 2008 | 442 | 0.060 |
Why?
|
| Necrosis | 2 | 1996 | 219 | 0.050 |
Why?
|
| Area Under Curve | 3 | 2011 | 340 | 0.050 |
Why?
|
| Spin Labels | 2 | 2015 | 108 | 0.050 |
Why?
|
| Biophysical Phenomena | 2 | 1995 | 126 | 0.050 |
Why?
|
| Biophysics | 2 | 1995 | 154 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2004 | 280 | 0.050 |
Why?
|
| Lactates | 1 | 2023 | 34 | 0.050 |
Why?
|
| Lead | 1 | 2023 | 35 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 1110 | 0.050 |
Why?
|
| General Surgery | 2 | 1996 | 264 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 100 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2023 | 118 | 0.050 |
Why?
|
| Aging | 1 | 2008 | 770 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2024 | 176 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2023 | 95 | 0.050 |
Why?
|
| Radiography | 3 | 2012 | 763 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 110 | 0.050 |
Why?
|
| Antigens, Polyomavirus Transforming | 2 | 2015 | 48 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2023 | 107 | 0.050 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2009 | 684 | 0.040 |
Why?
|
| Motion | 1 | 2022 | 96 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2025 | 3616 | 0.040 |
Why?
|
| beta Catenin | 1 | 2023 | 269 | 0.040 |
Why?
|
| Models, Statistical | 3 | 2011 | 602 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 2002 | 44 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2023 | 420 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2022 | 191 | 0.040 |
Why?
|
| Prognosis | 2 | 2026 | 4126 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 370 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 313 | 0.040 |
Why?
|
| Tibial Arteries | 1 | 2021 | 5 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 214 | 0.040 |
Why?
|
| Bacteria | 1 | 2025 | 546 | 0.040 |
Why?
|
| Fibula | 1 | 2021 | 33 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 370 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2023 | 9770 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 1775 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 108 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2020 | 194 | 0.040 |
Why?
|
| Indicator Dilution Techniques | 1 | 2019 | 6 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 370 | 0.040 |
Why?
|
| Young Adult | 3 | 2017 | 7568 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1947 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 1999 | 30 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 1999 | 179 | 0.040 |
Why?
|
| Microwaves | 1 | 1999 | 44 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 1999 | 126 | 0.030 |
Why?
|
| Fructose | 1 | 2018 | 38 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 81 | 0.030 |
Why?
|
| Random Allocation | 1 | 2018 | 312 | 0.030 |
Why?
|
| Weaning | 1 | 2017 | 26 | 0.030 |
Why?
|
| Radial Artery | 1 | 2017 | 41 | 0.030 |
Why?
|
| Adiposity | 1 | 2017 | 81 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2001 | 1094 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 206 | 0.030 |
Why?
|
| Pressure | 1 | 2017 | 174 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2551 | 0.030 |
Why?
|
| Time | 1 | 2016 | 80 | 0.030 |
Why?
|
| Sonication | 1 | 1996 | 5 | 0.030 |
Why?
|
| Thermal Conductivity | 1 | 1996 | 4 | 0.030 |
Why?
|
| Mathematics | 1 | 1996 | 176 | 0.030 |
Why?
|
| Auditory Perception | 1 | 1997 | 104 | 0.030 |
Why?
|
| Simian virus 40 | 1 | 2015 | 35 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 2471 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2026 | 2661 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 1214 | 0.030 |
Why?
|
| Edema | 1 | 2014 | 68 | 0.030 |
Why?
|
| Color | 1 | 2014 | 80 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 123 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 1999 | 2858 | 0.020 |
Why?
|
| Rabbits | 1 | 2014 | 582 | 0.020 |
Why?
|
| Mammography | 1 | 2017 | 504 | 0.020 |
Why?
|
| Streptozocin | 1 | 2012 | 56 | 0.020 |
Why?
|
| Perfusion | 1 | 2014 | 271 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2023 | 3633 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 341 | 0.020 |
Why?
|
| Fats | 1 | 2011 | 12 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 321 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 115 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 559 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2012 | 207 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2019 | 2599 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 47 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 375 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1255 | 0.020 |
Why?
|
| Fluorescence | 1 | 2011 | 100 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 214 | 0.020 |
Why?
|
| Intestines | 1 | 2013 | 442 | 0.020 |
Why?
|
| Angiography | 1 | 2011 | 194 | 0.020 |
Why?
|
| Ileum | 1 | 2011 | 179 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 402 | 0.020 |
Why?
|
| Extremities | 1 | 2011 | 173 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 2085 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 578 | 0.020 |
Why?
|
| Deuterium | 1 | 2008 | 34 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2008 | 102 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 435 | 0.020 |
Why?
|
| Microscopy | 1 | 2008 | 92 | 0.020 |
Why?
|
| Dogs | 2 | 1999 | 642 | 0.020 |
Why?
|
| Endoscopy | 1 | 2011 | 388 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1752 | 0.010 |
Why?
|
| Radiology | 1 | 2008 | 215 | 0.010 |
Why?
|
| Inflammation | 1 | 2011 | 1133 | 0.010 |
Why?
|
| Kidney | 2 | 1999 | 1121 | 0.010 |
Why?
|
| Ribs | 1 | 1999 | 49 | 0.010 |
Why?
|
| Lung | 1 | 1999 | 1408 | 0.010 |
Why?
|